This week, we look at the European Federation of Pharmaceutical Industries and Associations or EFPIA’s patient wait survey and its key findings as well as news developments in the spinal muscular atrophy world relating to gene therapy Novartis’ Zolgensma and Biogen’s Spinraza.
Presenter: Aparna Krishnan
Contributors: Sophie Schmitz, Jack Rawson
Producer: Aparna Krishnan
